Review of NICE Technology Appraisal Guidance No. 156; Routine antenatal anti-D prophylaxis for women who are rhesus D negative

TA156; Routine antenatal anti-D prophylaxis for women who are rhesus D negative was added to the static list in August 2011.

In 2014, the Institute received a request to re-consider this appraisal again in light of information relating to cffDNA testing which is likely to be offered to every rhesus negative pregnant woman via the Blood Transfusion Service, and which could reduce the need for anti-D treatment to all pregnant rhesus negative women.

The use of non-invasive fetal Rhd determination could only result in improved cost-effectiveness for the technologies in question as it would lead to a more targeted prophylaxis. The issue as to whether these savings justify the costs of a new diagnostic is beyond the remit of this appraisal.

The Institute could find no other evidence that may lead to a change in the existing recommendations. As a result, we have written to relevant stakeholders to inform them that TA156 will remain on the static list of technology appraisals.

March 2015